Anti-Cancer Drug Screening
We continue to expand our xenograft and orthotopic models for efficacy screening of drug candidates.
Our latest addition is a xenograft model in athymic nude mice for ovarian cancer – Human Cell Line OVCAR-5/RFP.
OVCAR-5 is a human epithelial carcinoma cell line of the ovary established from the ascetic fluid of a patient with progressive ovarian adenocarcinoma without prior cytotoxic treatment. The unique growth pattern of ovarian carcinoma makes it an ideal model for examining anticancer drug activity. In Vivo, OVCAR-5 cells can form moderately well-differentiated adenocarcinoma consistent with ovarian primary cells. The cell line stably expresses RFP and Puromycin resistant genes1.
WBI Cancer Models:
- Cancers: brain, breast, colon, liver, peripheral blood (leukemia), lung, skin (melanoma), pancreas, prostate, ovarian, thyroid.
- Animals: immunodeficient mice and rats.
- Orthotopic: breast and liver cancers.
- Tumor recoveries, preservation, weights, histology, metastasis observations.
Results: Rapid, reliable, statistical analysis and complete Final Reports.
1. Cell BioLabs, Inc. 2010-2011.
Indomethacin-Induced IBD Model
We have added a new model for Inflammatory Bowel Disease to our list of efficacy tests in this area.
In addition to in vivo models for TNBS-induced IBD and DSS-induced-IBD we now have available our validated Indomethacin-induced IBD model. Subcutaneous injection of Indomethacin to Wistar rats results in inflammation primarily of the small intestine. This model is also referred to as Small Intestine Injury. It is a valuable model for investigation of treatments for Crohn’s disease which mainly affects the last part of the Small Intestine (terminal ileum).
The Washington Biotechnology model provides a variety of readouts in a short (1-week) study.
- Disease sign scores at termination: adhesions, ulceration and inflammation
- Lengths of ulcerated and inflamed areas of the small intestine
- Colon length and weight
- Body weights daily
- Collection and preservation of Small Intestine or sections (duodenum, jejunum, ileum)
- Optional Items:
- Histopathology on all or part of the collected small intestine (scored readings,blocks, slides, photomicrographs)
- Blood samples for exposure (plasma or serum)
Prophylactic or therapeutic dosing regimens to assess compound efficacy.
As with any of our in vivo models, each study protocol is custom designed to meet Sponsor requirements.
References:
1. Boushey RP et al. Glucagon-like peptide 2 decreases mortality and reduces the severity on indomethacin-induced enteritis. Am J Physiol Endocrinol Metab 277:E937-E947, 1999.
2. Asano T et al. HSP70 Confers Protection against Indomethacin-Induced Lesions of the Small Intestine. J Pharmacol Exp Ther 330(2): 458-467, 2009.
3. Yamada T et al. Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation 17: 641-662, 1993.
4. Nygard GA et al. Acute indomethacin-induced jejunal injury in the rat: early morphological and biochemical changes. Gastroenterology 106:567-575, 1994.